Literature DB >> 9260149

New horizons: antiretroviral therapy in 1997.

A B Williams1.   

Abstract

Exciting advances in basic and clinical science brought a new strategy for antiretroviral therapy and new hope to people living with HIV in 1996. There are now three major categories of antiretroviral agents available for clinical use. All require replicating virus, and none are virucidal. The goal of antiretroviral therapy is a significant and prolonged reduction of the amount of actively replicating HIV (viral load). Carefully chosen combinations of antiretroviral drugs significantly reduce HIV load and are likely to extend life. However, not all patients respond to highly active antiretroviral therapy (HAART), and, for those who do, adjustment to demanding regimens and management of side effects may be difficult. The development of drug resistance is a serious concern, because resistance is associated with rising viral loads and with poorer prognosis in advanced disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9260149     DOI: 10.1016/S1055-3290(97)80011-8

Source DB:  PubMed          Journal:  J Assoc Nurses AIDS Care        ISSN: 1055-3290            Impact factor:   1.354


  4 in total

Review 1.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

2.  HIV/AIDS therapy and prevention: The two solitudes.

Authors:  Jocelyne Piret; Michel G Bergeron
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

3.  Epidemiology of classic and AIDS-related Kaposi's sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005.

Authors:  A W Armstrong; K H Lam; E P Chase
Journal:  Epidemiol Infect       Date:  2012-03-12       Impact factor: 4.434

4.  Structural basis of antiviral activity of peptides from MPER of FIV gp36.

Authors:  Manuela Grimaldi; Ilaria Stillitano; Giuseppina Amodio; Angelo Santoro; Michela Buonocore; Ornella Moltedo; Paolo Remondelli; Anna Maria D'Ursi
Journal:  PLoS One       Date:  2018-09-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.